US 12,459,976 B2
Peptides and their use in diagnosis
Bror Samuel Lundin, Mölndal (SE)
Assigned to Biotome Pty Ltd., West Perth (AU)
Filed by Biotome Pty Ltd., West Perth (AU)
Filed on May 31, 2024, as Appl. No. 18/680,407.
Application 18/680,407 is a continuation of application No. 17/852,797, filed on Jun. 29, 2022, granted, now 12,037,365.
Application 17/852,797 is a continuation of application No. 16/488,077, granted, now 11,401,308, issued on Aug. 2, 2022, previously published as PCT/EP2018/054396, filed on Feb. 22, 2018.
Claims priority of application No. 1750203-0 (SE), filed on Feb. 24, 2017.
Prior Publication US 2024/0309054 A1, Sep. 19, 2024
Int. Cl. G01N 33/569 (2006.01); C07K 14/205 (2006.01); G01N 33/574 (2006.01)
CPC C07K 14/205 (2013.01) [G01N 33/56922 (2013.01); G01N 33/57446 (2013.01); G01N 2333/205 (2013.01); G01N 2469/20 (2013.01)] 8 Claims
 
1. A method of diagnosis comprising the steps of:
a) providing a sample from a subject having, or suspected of having, a Helicobacter pylori infection and/or increased risk of gastric cancer in the subject,
b) contacting said sample with a peptide comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 26, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 280, and SEQ ID NO: 281, said peptide consisting of at most 25 amino acids, and
c) detecting specific binding of antibodies in the sample to the peptide, wherein presence of antibodies in the sample which specifically bind to the peptide is indicative of Helicobacter pylori infection and/or increased risk of gastric cancer in the subject.